High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: A phase I trial

Margaret Tempero, Peter Leichner, Janina Baranowska-Kortylewicz, Katherine Harrison, Sam Augustine, Jeffrey Schlom, James Anderson, James Lowell Wisecarver, David Colcher

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

A Phase I trial of increasing administered activities of 90yttrium (90Y)-labeled monoclonal antibody (MAb) CC49 was conducted to determine whether extrahematopoietic toxicity occurred with this radioimmunoconjugate. Twelve patients with various gastrointestinal tract cancers were administered a tracer dose of 111In-labeled MAb CC49 for biodistribution and pharmacokinetic studies. Patients then underwent a single treatment with increasing administered activities of 90Y-labeled MAb CC49 (0.3, 0.4, and 0.5 mCi/kg). Biodistribution studies, using 111In-labeled MAb CC49 as a surrogate, were determined using planar and single photon emission computed tomography imaging. Pharmacokinetic studies were performed by measuring radioactivity in blood samples taken at intervals after radioimmunoconjugate infusions. Tissue biopsies of tumor metastases and related normal tissues (liver and bone marrow) were obtained for radioactivity measurements. Radiation dosimetry estimates were calculated using these data. Toxicity was evaluated using the National Cancer Institute Common Toxicity Criteria. No dose limiting extrahematopoietic toxicity was identified in the range of administered activities used in this study. Radioimmunolocalization based on planar and single photon emission computed tomography images 111Inlabeled MAb CC49 showed heterogeneous (nonspecific) liver and erate uptake. The α and β half-lives of 111In-labeled MAb CC49 and 90Y-labeled MAb CC49 in the blood were similar. Absorbed radiation dose estimates in metastatic tumor sites ranged from 180 to 3000 cGy. The percentage of injected dose/kg of tumor ranged from 1.12 to 18.14; however, tumor:normal liver ratios were consistently <1. No objective responses were observed. Doses of up to 0.5 mCi/kg could be administered with reversible grade IV myelotoxicity. Absorbed radiation dose in tumor was suboptimal, even at the highest administered activity level. Deposition of 90Y in liver was high, and estimates of absorbed dose in liver equaled or exceeded that which could be achieved in metastatic tumor sites. Strategies to enhance access of radioimmunoconjugates in tumor and diminish deposition in the liver need to be developed for effective treatment using MAb CC49 with chelated radiometals.

Original languageEnglish (US)
Pages (from-to)3095-3102
Number of pages8
JournalClinical Cancer Research
Volume6
Issue number8
StatePublished - Aug 1 2000

Fingerprint

Monoclonal Antibodies
Immunoconjugates
Liver
Neoplasms
Therapeutics
Single-Photon Emission-Computed Tomography
Radioactivity
Pharmacokinetics
Radiation
Radiometry
Gastrointestinal Neoplasms
National Cancer Institute (U.S.)
Bone Marrow
Neoplasm Metastasis
Biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tempero, M., Leichner, P., Baranowska-Kortylewicz, J., Harrison, K., Augustine, S., Schlom, J., ... Colcher, D. (2000). High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: A phase I trial. Clinical Cancer Research, 6(8), 3095-3102.

High-dose therapy with 90yttrium-labeled monoclonal antibody CC49 : A phase I trial. / Tempero, Margaret; Leichner, Peter; Baranowska-Kortylewicz, Janina; Harrison, Katherine; Augustine, Sam; Schlom, Jeffrey; Anderson, James; Wisecarver, James Lowell; Colcher, David.

In: Clinical Cancer Research, Vol. 6, No. 8, 01.08.2000, p. 3095-3102.

Research output: Contribution to journalArticle

Tempero, M, Leichner, P, Baranowska-Kortylewicz, J, Harrison, K, Augustine, S, Schlom, J, Anderson, J, Wisecarver, JL & Colcher, D 2000, 'High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: A phase I trial', Clinical Cancer Research, vol. 6, no. 8, pp. 3095-3102.
Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J et al. High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: A phase I trial. Clinical Cancer Research. 2000 Aug 1;6(8):3095-3102.
Tempero, Margaret ; Leichner, Peter ; Baranowska-Kortylewicz, Janina ; Harrison, Katherine ; Augustine, Sam ; Schlom, Jeffrey ; Anderson, James ; Wisecarver, James Lowell ; Colcher, David. / High-dose therapy with 90yttrium-labeled monoclonal antibody CC49 : A phase I trial. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 8. pp. 3095-3102.
@article{7dd99d9af4f74040bbbc97f4481b07fe,
title = "High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: A phase I trial",
abstract = "A Phase I trial of increasing administered activities of 90yttrium (90Y)-labeled monoclonal antibody (MAb) CC49 was conducted to determine whether extrahematopoietic toxicity occurred with this radioimmunoconjugate. Twelve patients with various gastrointestinal tract cancers were administered a tracer dose of 111In-labeled MAb CC49 for biodistribution and pharmacokinetic studies. Patients then underwent a single treatment with increasing administered activities of 90Y-labeled MAb CC49 (0.3, 0.4, and 0.5 mCi/kg). Biodistribution studies, using 111In-labeled MAb CC49 as a surrogate, were determined using planar and single photon emission computed tomography imaging. Pharmacokinetic studies were performed by measuring radioactivity in blood samples taken at intervals after radioimmunoconjugate infusions. Tissue biopsies of tumor metastases and related normal tissues (liver and bone marrow) were obtained for radioactivity measurements. Radiation dosimetry estimates were calculated using these data. Toxicity was evaluated using the National Cancer Institute Common Toxicity Criteria. No dose limiting extrahematopoietic toxicity was identified in the range of administered activities used in this study. Radioimmunolocalization based on planar and single photon emission computed tomography images 111Inlabeled MAb CC49 showed heterogeneous (nonspecific) liver and erate uptake. The α and β half-lives of 111In-labeled MAb CC49 and 90Y-labeled MAb CC49 in the blood were similar. Absorbed radiation dose estimates in metastatic tumor sites ranged from 180 to 3000 cGy. The percentage of injected dose/kg of tumor ranged from 1.12 to 18.14; however, tumor:normal liver ratios were consistently <1. No objective responses were observed. Doses of up to 0.5 mCi/kg could be administered with reversible grade IV myelotoxicity. Absorbed radiation dose in tumor was suboptimal, even at the highest administered activity level. Deposition of 90Y in liver was high, and estimates of absorbed dose in liver equaled or exceeded that which could be achieved in metastatic tumor sites. Strategies to enhance access of radioimmunoconjugates in tumor and diminish deposition in the liver need to be developed for effective treatment using MAb CC49 with chelated radiometals.",
author = "Margaret Tempero and Peter Leichner and Janina Baranowska-Kortylewicz and Katherine Harrison and Sam Augustine and Jeffrey Schlom and James Anderson and Wisecarver, {James Lowell} and David Colcher",
year = "2000",
month = "8",
day = "1",
language = "English (US)",
volume = "6",
pages = "3095--3102",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - High-dose therapy with 90yttrium-labeled monoclonal antibody CC49

T2 - A phase I trial

AU - Tempero, Margaret

AU - Leichner, Peter

AU - Baranowska-Kortylewicz, Janina

AU - Harrison, Katherine

AU - Augustine, Sam

AU - Schlom, Jeffrey

AU - Anderson, James

AU - Wisecarver, James Lowell

AU - Colcher, David

PY - 2000/8/1

Y1 - 2000/8/1

N2 - A Phase I trial of increasing administered activities of 90yttrium (90Y)-labeled monoclonal antibody (MAb) CC49 was conducted to determine whether extrahematopoietic toxicity occurred with this radioimmunoconjugate. Twelve patients with various gastrointestinal tract cancers were administered a tracer dose of 111In-labeled MAb CC49 for biodistribution and pharmacokinetic studies. Patients then underwent a single treatment with increasing administered activities of 90Y-labeled MAb CC49 (0.3, 0.4, and 0.5 mCi/kg). Biodistribution studies, using 111In-labeled MAb CC49 as a surrogate, were determined using planar and single photon emission computed tomography imaging. Pharmacokinetic studies were performed by measuring radioactivity in blood samples taken at intervals after radioimmunoconjugate infusions. Tissue biopsies of tumor metastases and related normal tissues (liver and bone marrow) were obtained for radioactivity measurements. Radiation dosimetry estimates were calculated using these data. Toxicity was evaluated using the National Cancer Institute Common Toxicity Criteria. No dose limiting extrahematopoietic toxicity was identified in the range of administered activities used in this study. Radioimmunolocalization based on planar and single photon emission computed tomography images 111Inlabeled MAb CC49 showed heterogeneous (nonspecific) liver and erate uptake. The α and β half-lives of 111In-labeled MAb CC49 and 90Y-labeled MAb CC49 in the blood were similar. Absorbed radiation dose estimates in metastatic tumor sites ranged from 180 to 3000 cGy. The percentage of injected dose/kg of tumor ranged from 1.12 to 18.14; however, tumor:normal liver ratios were consistently <1. No objective responses were observed. Doses of up to 0.5 mCi/kg could be administered with reversible grade IV myelotoxicity. Absorbed radiation dose in tumor was suboptimal, even at the highest administered activity level. Deposition of 90Y in liver was high, and estimates of absorbed dose in liver equaled or exceeded that which could be achieved in metastatic tumor sites. Strategies to enhance access of radioimmunoconjugates in tumor and diminish deposition in the liver need to be developed for effective treatment using MAb CC49 with chelated radiometals.

AB - A Phase I trial of increasing administered activities of 90yttrium (90Y)-labeled monoclonal antibody (MAb) CC49 was conducted to determine whether extrahematopoietic toxicity occurred with this radioimmunoconjugate. Twelve patients with various gastrointestinal tract cancers were administered a tracer dose of 111In-labeled MAb CC49 for biodistribution and pharmacokinetic studies. Patients then underwent a single treatment with increasing administered activities of 90Y-labeled MAb CC49 (0.3, 0.4, and 0.5 mCi/kg). Biodistribution studies, using 111In-labeled MAb CC49 as a surrogate, were determined using planar and single photon emission computed tomography imaging. Pharmacokinetic studies were performed by measuring radioactivity in blood samples taken at intervals after radioimmunoconjugate infusions. Tissue biopsies of tumor metastases and related normal tissues (liver and bone marrow) were obtained for radioactivity measurements. Radiation dosimetry estimates were calculated using these data. Toxicity was evaluated using the National Cancer Institute Common Toxicity Criteria. No dose limiting extrahematopoietic toxicity was identified in the range of administered activities used in this study. Radioimmunolocalization based on planar and single photon emission computed tomography images 111Inlabeled MAb CC49 showed heterogeneous (nonspecific) liver and erate uptake. The α and β half-lives of 111In-labeled MAb CC49 and 90Y-labeled MAb CC49 in the blood were similar. Absorbed radiation dose estimates in metastatic tumor sites ranged from 180 to 3000 cGy. The percentage of injected dose/kg of tumor ranged from 1.12 to 18.14; however, tumor:normal liver ratios were consistently <1. No objective responses were observed. Doses of up to 0.5 mCi/kg could be administered with reversible grade IV myelotoxicity. Absorbed radiation dose in tumor was suboptimal, even at the highest administered activity level. Deposition of 90Y in liver was high, and estimates of absorbed dose in liver equaled or exceeded that which could be achieved in metastatic tumor sites. Strategies to enhance access of radioimmunoconjugates in tumor and diminish deposition in the liver need to be developed for effective treatment using MAb CC49 with chelated radiometals.

UR - http://www.scopus.com/inward/record.url?scp=0033903713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033903713&partnerID=8YFLogxK

M3 - Article

C2 - 10955789

AN - SCOPUS:0033903713

VL - 6

SP - 3095

EP - 3102

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -